PRKAR1A and neoplasm: Treating with a 10 μg/mL (8.13 μM) concentration of TSE1 completely inhibited tube formation in human umbilical vein endothelial cells, as well as TSE1 showing toxicity toward cancer cells and inhibiting in vivo growth of the tumor [17].